Home Health Moderna and Merck Revive mRNA Hopes With Melanoma Success
Health

Moderna and Merck Revive mRNA Hopes With Melanoma Success

Key Points

A personalized vaccine developed by Moderna Inc. and Merck & Co. reduced the recurrence of melanoma in a large, late-stage trial, raising expectations for treating the deadliest form of skin cancer and showing the promise of the embattled mRNA technology. Bloomberg's Sam Fazeli joins to discuss.

A personalized vaccine developed by Moderna Inc. and Merck & Co. reduced the recurrence of melanoma in a large, late-stage trial, raising expectations for treating the deadliest form of skin cancer and showing the promise of the embattled mRNA technology. Bloomberg's Sam Fazeli joins to discuss. (Source: Bloomberg)
Moderna (ORG) Merck (ORG) Moderna Inc. (ORG) Merck & Co. (ORG) mRNA (ORG) Bloomberg (ORG) Sam Fazeli (PERSON)
Originally published by Bloomberg Technology Read original →